Yousif Capital Management LLC Has $2.01 Million Position in Repligen Co. (NASDAQ:RGEN)

Yousif Capital Management LLC cut its stake in Repligen Co. (NASDAQ:RGEN) by 2.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,811 shares of the biotechnology company’s stock after selling 426 shares during the quarter. Yousif Capital Management LLC’s holdings in Repligen were worth $2,012,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of RGEN. Van ECK Associates Corp increased its stake in Repligen by 7.8% in the fourth quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company’s stock valued at $6,078,000 after purchasing an additional 3,066 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Repligen by 1.9% in the 4th quarter. Rhumbline Advisers now owns 146,149 shares of the biotechnology company’s stock valued at $21,037,000 after buying an additional 2,739 shares during the period. Congress Asset Management Co. grew its holdings in shares of Repligen by 12.4% in the 4th quarter. Congress Asset Management Co. now owns 116,620 shares of the biotechnology company’s stock valued at $16,786,000 after buying an additional 12,856 shares during the period. CIBC Asset Management Inc increased its position in shares of Repligen by 5.0% in the 4th quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock valued at $246,000 after buying an additional 81 shares in the last quarter. Finally, Rice Hall James & Associates LLC acquired a new stake in Repligen during the 4th quarter worth $2,215,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on RGEN. Wall Street Zen upgraded Repligen from a “sell” rating to a “hold” rating in a report on Thursday, May 8th. HC Wainwright reissued a “buy” rating and set a $180.00 target price on shares of Repligen in a research note on Monday, May 5th. JPMorgan Chase & Co. cut their price target on shares of Repligen from $200.00 to $190.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 29th. Canaccord Genuity Group reduced their price target on shares of Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a report on Wednesday, April 16th. Finally, Evercore ISI began coverage on shares of Repligen in a report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price objective on the stock. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, Repligen has an average rating of “Moderate Buy” and an average target price of $173.25.

Repligen Stock Down 2.9%

Shares of RGEN stock opened at $127.52 on Monday. The firm’s fifty day moving average price is $128.58 and its two-hundred day moving average price is $142.86. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a 1 year low of $102.97 and a 1 year high of $182.52. The firm has a market capitalization of $7.16 billion, a P/E ratio of -250.04, a PEG ratio of 4.54 and a beta of 1.10.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.04. The company had revenue of $169.17 million during the quarter, compared to analysts’ expectations of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Repligen’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.28 EPS. On average, equities analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.